Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 3;10:1672. doi: 10.1038/s41598-020-58382-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Tolvaptan improves renal survival and cystic parameters, while pioglitazone does not. (a) Renal survival of untreated mice (n = 20) versus treated mice (n = 20 or 21). (b) 2KW/BW% when mice reached ESRD or at the end of the experiment. (c) Cystic indices of mice at ESRD or at the end of the experiment. Differences between single-drug treatment with tolvaptan-SD and the combination treatment were non-significant. (d) Representative images of PAS-stained kidney sections from each treatment group. For each group, the image corresponding to the median 2KW/BW% is shown. (e) Gene expression of selected fibrosis markers in wildtype, untreated (i.e. cystic) iKspCre-Pkd1^del kidneys and pioglitazone-treated iKspCre-Pkd1^del kidneys. Each data point represents a single mouse. The Log Rank (Mantel-Cox) test was used for the Kaplan-Meier survival analyses. Data represent the mean ± SD. Significance was measured by one-way ANOVA followed by Tukey’s multiple comparisons test. n.s.: non-significant, 2KW/BW%: 2 kidneys weight to body weight ratio, WT: wildtype, AU: arbitrary units.